Biological response to radiation therapy

Acta Oncologica

Volumn 42, Issue 2, 2003, Pages 92-106

  Turesson, Ingela ^a,d   Carlsson, Jörgen ^a   Brahme, Anders ^b   Glimelius, Bengt ^a,b   Zackrisson, Björn ^c   Stenerlöw, Bo ^a   Forssell Aronsson, Eva ^e   Hellström, Mikael ^e   Johansson, Karl Axel ^e   Kjellén, Elisabeth ^e   Littbrand, Bo ^e   Mattson, Sören ^e   Nordenskjöld, Bo ^e  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; OPTIMIZATION; TISSUE;

RADIATION BIOLOGY;

RADIOTHERAPY;

BYSTANDER EFFECT; CANCER CELL; CANCER RADIOTHERAPY; CANCER RESEARCH; CELL PROLIFERATION; CLONOGENESIS; MEDICAL SOCIETY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOBIOLOGY; REVIEW; STEM CELL; SWEDEN; TISSUE REACTION; TREATMENT PLANNING;

BYSTANDER EFFECT; CELL DIVISION; CLONE CELLS; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; RADIATION DOSAGE; RADIATION ONCOLOGY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; SIGNAL TRANSDUCTION; STEM CELLS; SWEDEN;

EID: 0037539918     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004959     Document Type: Review

References (69)

1. Rich T, Allen RL, AH W. Defying death after DNA damage. Nature 2000; 407: 777-783.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
3. Tanya TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000; 10: 886-95.
4. van Gent DC, Hoeimakers JHJ, Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet 2001; 2: 196-206.
5. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
6. Steel GG. The case against apoptosis. Acta Oncol 2001; 40: 968-75.
7. Taccioli GE, Gottlieb TM, Blunt T, et al. Ku80: product of the XRCC5 gene and its role in DNA repair and V(D)J recombination. Science 1994; 265: 1442-5.
8. Stone HB, Dewey WC, Wallace SS, et al. Molecular biology to radiation oncology: a model for translational research? Opportunities in basic and translational research. Radiat Res 1998; 150: 134-47.
9. Smilenov LB, Brenner DJ, Hall EJ. Modest increased sensitivity to radiation oncogenesis in ATM heterozygous versus wild-type mammalian cells. Cancer Res 2001; 61: 5710-3.
10. Andreassen C, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basis - where and how to look for it? Radiother Oncol 2002; 64: 131.
11. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
12. Kummermehr JC. Tumour stem cells - the evidence and the ambiguity. Acta Oncol 2001; 40: 981-8.
13. Bach SP, Renehan AG, Potten CS. Stem cells: the intestinal stem cell as a paradigm. Carcinogenesis 2000; 21: 469-76.
14. Shackney SE, Shankey TV. Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. Cytometry 1999; 35: 97-116.
15. Wilson GD. A new look at proliferation. Acta Oncol 2001; 40: 989-94.
16. Turesson I, Bernefors R, Book M, et al. Normal tissue response to low doses of radiotherapy assessed by molecular markers. A study of skin in patients treated for prostate cancer. Acta Oncol 2001; 40: 941-51.
17. Begg AC, Haustermans K, Hart AA, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother Oncol 1999; 50: 13-23.
18. Corvo R, Paoli G, Giaretti W, et al. Evidence of cell kinetics as a predictive factor of response to radiotherapy alone or chemoradiotherapy in patients with advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2000; 47: 57-63.
19. Haustermans K, Fowler JF. Is there a future for cell kinetic measurements using IdUrd or BdUrd? Int J Radiat Oncol Biol Phys 2001; 49: 505-11.
20. Wilson GD. Tpot and head and neck cancer: where are we now? Anticancer Res 1998; 18: 4801-5.
21. Fowler J. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001; 40: 712-7.
22. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (Low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002; 52: 6-13.
23. Joiner MC. Models of radiation cell killing. In: Steel GG, ed. Basic clinical radiobiology, 2nd ed. London: Arnold; 1997. p. 52-7.
24. Joiner MC, van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, ed. Basic clinical radiobiology, 2nd ed. London: Arnold; 1997. p. 106-21.
25. Brenner DJ, Hlatky LR, Hahnfeldt PJ, et al. The linear-quadratic model and most other common radiobiological models result in similar predictions of time-dose relationships. Radiat Res 1998; 150: 83-91.
26. Thames Jr HD, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219-26.
27. Williams MV, Denekamp J, Fowler JF. A review of α/β ratio for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 1985; 11: 87-96.
28. Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880-914.
29. Tubiana M, Eschwege F. Conformal radiotherapy and intensity-modulated radiotherapy - clinical data. Acta Oncol 2000; 39: 555-67.
30. Schultheiss TE. The controversies and pitfalls in modeling normal tissue radiation injury/damage. Semin Radiat Oncol 2001; 11: 210-4.
31. Yorke ED. Modeling the effects of inhomogeneous dose distributions in normal tissues. Semin Radiat Oncol 2001; 11: 197-209.
32. Marples B, Joiner MC. The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population. Radiat Res 1993; 133: 41-51.
33. Marples B, Lambin P, Skov KA, et al. Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int J Radiat Biol 1997; 71: 721-35.
34. Joiner MC, Marples B, Lambin P, et al. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys 2001; 49: 379-89.
35. Wouters BG, Sy AM, Skarsgard LD. Low-dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat Res 1996; 146: 399-413.
36. Short SC, Kelly J, Mayes CR, et al. Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int J Radiat Biol 2001; 77: 655-64.
37. Joiner MC, Denekamp J, Maughan RL. The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin. Int J Radiat Biol 1986; 49: 565-80.
38. Joiner MC, Johns H. Renal damage in the mouse: the response to very small doses per fraction. Radiat Res 1988; 114: 385-98.
39. Withers HR. Biological aspects of conformal therapy. Acta Oncol 2000; 39: 569-77.
40. Brenner DJ, Curtis RE, Hall EJ. et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88: 398-406.
41. Travis L. Therapy-associated secondary solid cancer. Acta Oncol 2002; 41: 323-33.
42. Mothersill C, Seymour C. Radiation-induced bystander effects: past history and future directions. Radiat Res 2001; 155: 759-67.
43. Wu LJ, Randers-Pehrson G, Xu A, et al. Targeted cytoplasmic irradiation with alpha particles induces mutations in mammalian cells. Proc Natl Acad Sci USA 1999; 96: 4959-64.
44. Azzam EI, de Toledo SM, Little JB. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc Natl Acad Sci USA 2001; 98: 473-8.
45. Mothersill C, Seymour C. Medium from irradiated human epithelial cells but not human fibroblasts reduces the clonogenic survival of unirradiated cells. Int J Radiat Biol 1997; 71: 421-7.
46. Brahme A. Development of radiation therapy optimization. Acta Oncol 2000; 39: 579-95.
47. Brahme A, Nilsson J, Belkic D. Biologically optimized radiation therapy. Acta Oncol 2001; 40: 725-34.
48. Coleman CN. Radiation oncology - linking technology and biology in the treatment of cancer. Acta Oncol 2002; 41: 6-13.
49. Hall EJ. Do no harm - normal tissue effects. Acta Oncol 2001; 40: 913-6.
50. Lind BK, Persson LM, Edgren MR, et al. Repairable conditionally repairable damage model based on dual Poisson processes. Radiat Res 2003 (in press).
51. Ågren-Cronquist AK. Qualification of the response of heterogeneous turnouts and organized tissues to fractionated radiotherapy. Stockholm University. Thesis; 1995.
52. Turesson I, Joiner MC. Clinical evidence of hypersensitivity to low doses in radiotherapy. Radiother Oncol 1996; 40: 1-3.
53. Brahme A, ed. Dosimetric precision requirements and quantities for characterizing the response of tumours and normal tissues. In: Radiation dose in radiotherapy from prescription to delivery. Rio de Janeiro: IAEA; 1996. p. 49-65.
54. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997; 24: 103-10.
55. Nordic Association of Clinical Physics (NACP). Specification of dose delivery in radiation therapy. Acta Oncol 1997; 36 (Suppl 10): 1-32.
56. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Radiol Oncol 1984; 23: 379-91.
57. Kallman P, Ågren A, Brahme A. Turnout and normal tissue responses to fractionated non-uniform dose delivery. Int J Rad Biol 1992; 62: 249-62.
58. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001; 40: 712-7.
59. Ågren-Cronquist A-K, Källman P, Turesson I, et al. Volume and heterogeneity dependence of dose-response relationship for head and neck tumours. Acta Oncol 1995; 34: 851-60.
60. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-22.
61. Rubin P. A direction for clinical radiation pathology. The tolerance dose. In: Vaeth JM, ed. Front Rad Ther Oncol. Basel: S Karger; 1972. p. 1-16.
62. Thames HD, Hendry JH, eds. Fractionation in radiotherapy. London: Taylor & Francis; 1987.
63. Wigg DR. Applied radiobiology and bioeffect planning. Madison Wis: Med Phys Publish; 2001.
64. Gagliardi G Modeling heart and lung complication data in radiation therapy of the breast: Stockholm University: Thesis; 1998.
65. Gagliardi G, Bjohle J, Lax I, et al. Radiation pneumonitis after breast cancer irradiation: analysis of the complication probability using the relative seriality model. Int J Radiat Oncol Biol Phys 2000; 46: 373-81.
66. Brahme A, Ågren A. On the optimal dose distribution for eradication of heterogeneous tumours. Acta Oncol 1988; 26: 377-85.
67. Jones B, Dale RG. Mathematical models of tumour and normal tissue response. Acta Oncol 1999; 38: 883-93.
68. Olive PL, Banáth JP, Aquino-Parsons C. Measuring hyopoxia in solid tumours. Is there a gold standard? Acta Oncol 2001; 40: 917-23.
69. Withers HR, Taylor JMG, Maciejewski B. Treatment volume and tissue tolerance. Int J Radiat Oncol Biol Phys 1988; 104: 751-9.